Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in KSHV-infected Dilated Cardiomyopathy
NCT06236022Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in dilated cardiomyopathy (DCM) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Cardiac mortality at 36 months and Rate of heart transplantation at 36 months. Started Jan 2024; status: recruiting.
02
Drugs
sirolimus
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT06236022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236022.